Plain-English translation of NCT07391618 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a chemotherapy treatment approach using levofolinate for injection and 5-FU (a common chemotherapy drug) given together as a first-line treatment for advanced colorectal cancer. The study will evaluate how well this medication combination works and how safe it is for patients whose cancer has spread or cannot be surgically removed. Depending on genetic markers in your tumor and where the cancer started, you may also receive additional medications to enhance the treatment.
Advanced colorectal cancer is difficult to treat, and doctors are looking for better first-line treatment options that are both effective and manageable for patients. This trial is testing whether this specific combination of medications can improve outcomes for people with this serious diagnosis.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous chemotherapy infusions containing levofolinate and 5-FU on a regular schedule as part of standard chemotherapy regimens (either mFOLFOX6 or FOLFIRI). Depending on your tumor's genetic characteristics and location, your research team may also add a targeted medication like cetuximab or bevacizumab. You will have regular clinic visits for infusions, blood tests to monitor your health and tumor response, and imaging scans to see how the treatment is working.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Chinese PLA General Hospital
Enrollment target
~583 participants
Started
May 2025
Primary completion
December 2028
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Guanghai Dai
Chinese PLA General Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.